No adverse impact on serum lipids of the irreversible aromatase inactivator aromasin (R) (Exemestane (E)) in first line treatment of metastatic breast cancer (MBC) : companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacia and Upjohn

Author(s)

Journal

  • Proc Am Soc Clin Oncol

    Proc Am Soc Clin Oncol 20, 43a, 2001

Cited by:  1

Codes

  • NII Article ID (NAID)
    10011164258
  • Article Type
    Journal Article
  • Data Source
    CJPref 
Page Top